Nucleoside-modified VEGFC mRNA induces organ-specific lymphatic growth and reverses experimental lymphedema
Dysfunction of the lymphatic system leads to secondary lymphedema and results in degradation of quality of life. Here, the authors show that delivery of nucleoside-modified Vascular Endothelial Growth Factor C (VEGFC) mRNA, encapsulated in lipid nanoparticles, induces organ-specific lymphatic growth...
Guardado en:
Autores principales: | Dániel Szőke, Gábor Kovács, Éva Kemecsei, László Bálint, Kitti Szoták-Ajtay, Petra Aradi, Andrea Styevkóné Dinnyés, Barbara L. Mui, Ying K. Tam, Thomas D. Madden, Katalin Karikó, Raghu P. Kataru, Michael J. Hope, Drew Weissman, Babak J. Mehrara, Norbert Pardi, Zoltán Jakus |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e53077cda0b04c41bea9adf1cf679075 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Topical tacrolimus for the treatment of secondary lymphedema
por: Jason C. Gardenier, et al.
Publicado: (2017) -
Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies
por: Norbert Pardi, et al.
Publicado: (2018) -
Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge
por: Norbert Pardi, et al.
Publicado: (2017) -
CD4+ T cells are activated in regional lymph nodes and migrate to skin to initiate lymphedema
por: Gabriela D. García Nores, et al.
Publicado: (2018) -
Author Correction: VEGFC negatively regulates the growth and aggressiveness of medulloblastoma cells
por: Manon Penco-Campillo, et al.
Publicado: (2020)